Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: An electronic apparatus including a display unit having a signal transmission region, an active region surrounding at least a portion of the signal transmission region, and a peripheral region adjacent to the active region, and an input sensor including sensing electrodes each having a plurality of sensing electrode patterns which overlap the active region and a sensing circuit having a sensing pattern overlapping the signal transmission region and a sensing line connected to the sensing pattern, and on the display unit, wherein a hole passing through the display unit and the input sensor is defined to correspond to the signal transmission region, and in a plan view, a portion of the sensing pattern either overlaps the floating pattern or is between the sensing electrode patterns and the floating pattern, and the other portion of the sensing pattern is between the floating pattern and the hole.

Abstract: The present disclosure is directed to compounds of formula (1): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: A display device includes a base layer having a plurality of pixel regions and a non-pixel region surrounding the plurality of pixel regions, a circuit layer including a plurality of insulating layers and a plurality of conductive patterns, a light-emitting element layer, and an input sensing unit including a sensing pattern overlapping the non-pixel region. The light-emitting element layer includes a pixel defining structure overlapping the non-pixel region, and a plurality of light-emitting elements. The pixel defining structure includes a step pattern surrounding a portion of each of the plurality of pixel regions. The plurality of conductive patterns include a shielding pattern on the plurality of insulating layers and overlapping at the step pattern in a plan view, at least a portion of the shielding pattern being applied with voltage.

Abstract: An electronic apparatus including a display unit having a signal transmission region, an active region surrounding at least a portion of the signal transmission region, and a peripheral region adjacent to the active region, and an input sensor including sensing electrodes each having a plurality of sensing electrode patterns which overlap the active region and a sensing circuit having a sensing pattern overlapping the signal transmission region and a sensing line connected to the sensing pattern, and on the display unit, wherein a hole passing through the display unit and the input sensor is defined to correspond to the signal transmission region, and in a plan view, a portion of the sensing pattern either overlaps the floating pattern or is between the sensing electrode patterns and the floating pattern, and the other portion of the sensing pattern is between the floating pattern and the hole.

Abstract: This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is —CH2CH?C(CH3)2, R2 is methyl, R3 is CsHn, R4 is —C(O)N(R4a)(R4b), R5 is H, R6 is OH, and R7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.

Abstract: The present disclosure is directed to compounds of formula (I): wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: The present disclosure is directed to compounds of formula (1): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.

Abstract: This disclosure relates generally to cannabinoid derivatives having the formula (I), wherein R4 is hydrogen, —C(Q1)N(R4a)(R4b) or —C(R4J)(R4k)N(R4e)C(0)R4f, R6 is hydrogen, —C(Q2)N(R6a)(R6b) or —C(R6J)(R6k)N(R6e)C(0)R6f, provided that R6 is not hydrogen when R4 is hydrogen. Pharmaceutical compositions for the prevention or treatment of a disease associated with a cannabinoid receptor (such as CB1 or CB2) in a subject in need thereof, and methods of using the cannabinoid derivatives are also described.

Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: The present invention relates to a cosmetic composition for wrinkle reduction comprising, as an active ingredient, a Gynostemma pentaphyllum gypenoside fraction and, more specifically, to a cosmetic composition for wrinkle reduction, wherein the Gynostemma pentaphyllum gypenoside fraction includes at least one gypenoside selected from the group consisting of gypenoside UL1, gypenoside UL2, gypenoside UL3, gypenoside UL4, gypenoside UL5, gypenoside UL6, and gypenoside UL7.

Abstract: The present invention relates to Nelumbo nucifera callus having an increased content of gallic acid or an extract thereof and to a method for preparing the same. The Nelumbo nucifera callus extract according to the present invention has an excellent whitening effect by containing a large amount of gallic acid, and thus can be advantageously used as a cosmetic composition.

Abstract: A flexible touch screen panel includes a substrate having flexibility, sensing electrodes on at least one surface of the substrate, and implemented using an opaque conductive metal, and a polarizing plate on the substrate having the sensing electrodes formed thereon. The sensing electrodes may be implemented in a mesh shape having a plurality of openings.

Abstract: A flexible touch screen panel includes a substrate having flexibility, sensing electrodes on at least one surface of the substrate, and implemented using an opaque conductive metal, and a polarizing plate on the substrate having the sensing electrodes formed thereon. The sensing electrodes may be implemented in a mesh shape having a plurality of openings.

Abstract: The present invention relates to an ion exchange membrane and a manufacturing method therefor and, more specifically, to an ion exchange membrane comprising a cross-linked sulfonated triblock copolymer and carbon nanotube, which is utilizable in a redox flow energy storage device, etc. due to high ion conductivity, mechanical strength and ion selectivity. The ion exchange membrane of the present invention has superior ion selectivity and mechanical strength and thus can greatly improve the performance of a fuel battery, etc. when applied thereto.

Abstract: The present invention relates to Nelumbo nucifera callus having an increased content of gallic acid or an extract thereof and to a method for preparing the same. The Nelumbo nucifera callus extract according to the present invention has an excellent whitening effect by containing a large amount of gallic acid, and thus can be advantageously used as a cosmetic composition.

Abstract: The present invention relates to a cosmetic composition for wrinkle reduction comprising, as an active ingredient, a Gynostemma pentaphyllum gypenoside fraction and, more specifically, to a cosmetic composition for wrinkle reduction, wherein the Gynostemma pentaphyllum gypenoside fraction includes at least one gypenoside selected from the group consisting of gypenoside UL1, gypenoside UL2, gypenoside UL3, gypenoside UL4, gypenoside UL5, gypenoside UL6, and gypenoside UL7.